Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020 - WDAM.COM - TV 7 - News, Weather and Sports

Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, June 26, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020

http://www.reportlinker.com/p02182905/Stem-Cell-Therapy-Market-by-Treatment-Mode-Autologous--Allogeneic-Therapeutic-Applications-CNS-CVS-GIT-Wound-Healing-Musculoskeletal-Eye--Immune-System---Regulatory-Landscape-Pipeline-Analysis--Global-Forecasts-to-2020.html

The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market.

In this report, the global stem cell therapy market has been segmented on the basis of mode of therapy (allogeneic and autologous stem cell therapy) and therapeutic applications (eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others). The allogeneic stem cell therapy market is expected to hold the largest share of the global stem cell therapy market by 2015. This large share can be attributed to the launch of the first-in-class stem cell therapy called prochymal (Osiris Therapeutics, Inc., U.S.), for the treatment of acute graft-versus-host disease (GVHD) in children. This allogeneic therapy was approved in New Zealand and Canada, in May 2012.

Additionally, allogeneic stem cell therapy market is expected to grow at a higher CAGR as compared to the autologous stem cell therapy. Factors such as wider therapeutic applications, easier production scale up, and larger number of ongoing clinical trials of allogeneic stem cell therapies compared to autologous stem cell therapies are stimulating its market growth.

Geographically, North America is forecasted to command the largest share of the global stem cell therapy market in 2015, followed by Asia-Pacific. A number of factors such as extensive government funding and increasing grant of orphan drug status for stem cell therapeutics by FDA, and presence of major leading companies are driving the growth of the stem cell therapy market in North America. However, the economic slowdown and unfavorable reimbursement scenario for the stem cell therapy constraints the growth of the market in this region. The Asia-Pacific region is poised to grow at the highest CAGR in the next five years. Factors such as huge patient population base, increasing regulatory support through favorable government policies, strong product pipeline of stem cell therapies, and rising licensing activities are propelling the growth of the stem cell therapy market in the Asia-Pacific region.

Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are adopting several growth strategies such as new product approvals, partnerships/agreements/collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysis-industry analysis (pipeline analysis and investor's network), regulatory scenario, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high growth segments of the stem cell therapy market, high-growth regions and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities. The above mentioned market research data, current market size, and forecast of future trends will help existing players and new entrants to make the necessary decisions regarding the product offerings, geographic focus, change in strategic approach, R&D investments for innovation in products and technologies, and levels of output in order to remain successful.

Companies purchasing the report could use any one or combination of the below mentioned five strategies for reaping the market share.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on stem cell therapy pipeline product portfolio offered by the top players in the stem cell therapy market. The report analyzes the products market by category/end user across geographies

• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product approvals in the stem cell therapy market


• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various stem cell therapy products across geographies

• Market Diversification: Exhaustive information about pipeline products, targeted disease area, untapped geographies, recent developments, and investments in the stem cell therapy market


• Competitive Assessment: In-depth assessment of market shares for pipeline products, strategies, targeted disease area, distribution networks, and manufacturing capabilities of leading players in the stem cell therapy market

Table of Contents

1 INTRODUCTION
1.1 Objectives
1.2 Markets Covered
1.3 Stakeholders
1.4 Market Size Estimation
1.4.1 Market Definition
1.4.2 Market Scope
1.5 Research Methodology
1.5.1 Secondary Research
1.5.2 Primary Research
1.5.3 Analysis & Output
1.5.4 Assumptions
1.5.5 Limitations
1.5.6 Key Data Points Taken From Secondary Sources
1.5.7 Key Data Points Taken From Primary Sources

2 EXECUTIVE SUMMARY

3 MARKET DYNAMICS
3.1 Introduction
3.2 Drivers
3.2.1 Increasing Funding for New Stem Cell Lines
3.2.2 Development of Advanced Genomic Methods for Stem Cell Analysis
3.2.3 Increasing Focus on Human Embryonic Stem Cells
3.2.4 Increasing Approvals of Clinical Trials for Stem Cells Therapy
3.3 Restraints
3.3.1 Lack of Required Infrastructures
3.3.2 Difficulties Related with the Preservation Of Stem Cells
3.3.3 Ethical Issues Related to Embryonic Stem (ES) Cell
3.3.4 Immunorejection After Stem Cell Transplantation
3.3.5 Complexity Involved in Identification of Stem Cells in Adult Tissues
3.4 Opportunities
3.4.1 Lack of Effective Treatments to Cure Diseases
3.4.2 Evolution of New Stem Cell Therapies
3.4.3 Emergence of Induced Pluripotent Stem (IPS) Cells as an Alternative to Escs
3.4.4 Emerging Markets Unfolds New Avenues due to Low Regulatory Barriers and Clinical Trial Cost
3.5 Challenges
3.5.1 Dearth of Reimbursements
3.5.2 High Costs Incurred in Stem Cell Processing
3.5.3 Need of Automated Cell Culturing
3.5.4 Lack of Clear Regulatory Guidelines
3.6 Winning Imperatives
3.6.1 Partnering With Academic Institutes
3.6.2 Collaborating With Giant Pharmaceutical Firms
3.6.3 High Focus on Emerging Markets
3.7 Burning Issues
3.7.1 Establishment of Safety Profiles for Stem Cell Therapy
3.7.2 Granting Orphan Drug Status to Stem Cell Therapeutics

4 PIPELINE ANALYSIS

5 INVESTOR NETWORK

6 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY
6.1 Introduction
6.2 Allogeneic Stem Cell Therapy Market, By Application
6.2.1 Introduction
6.2.2 Eye Diseases
6.2.3 GIT diseases
6.2.4 Immune System Diseases
6.2.5 Metabolic Diseases
6.2.6 Musculoskeletal Disorders
6.2.7 CNS Diseases
6.2.8 CVS Diseases
6.2.9 Wounds and Injuries
6.2.10 Other Diseases
6.3 Autologous Stem Cell Therapy, By Application
6.3.1 Introduction
6.3.2 GIT diseases
6.3.3 CNS Diseases
6.3.4 Musculoskeletal Disorders
6.3.5 Wounds and Injuries
6.3.6 CVS Diseases
6.3.7 Other Diseases

7 GLOBAL STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATIONS
7.1 Introduction
7.2 Eye Diseases
7.3 GIT diseases
7.4 Immune System Diseases
7.5 Metabolic Diseases
7.6 Musculoskeletal Disorders
7.7 CNS Diseases
7.8 CVS Diseases
7.9 Wounds and Injuries
7.10 Other Diseases

8 REGULATORY LANDSCAPE
8.1 North America
8.2 Asia-Pacific
8.3 Europe
8.4 RoW (Rest of the World)

9 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY
9.1 Introduction
9.2 North America
9.3 Europe
9.4 Asia-Pacific
9.5 RoW (Rest of the World)

10 COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Competitive Situation & Trends

11 COMPANY PROFILES
11.1 Aastrom Biosciences Inc.
11.2 Advanced Cell Technologies, Inc.
11.3 Athersys Inc.
11.4 Celgene Corporation
11.5 Cellular Dynamics International
11.6 Cytori Therapeutics, Inc.
11.7 Fibrocell Science, Inc.
11.8 Gamida Cell Ltd.
11.9 Mesoblast Ltd.
11.10 Pluristem Therapeutics Inc.
11.11 StemCells Inc.

List Of Tables (57 Tables)

TABLE 1 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY, 2013–2020 ($MILLION)
TABLE 2 INVESTOR NETWORK FOR STEM CELL THERAPY MARKET: PRIVATE AND GOVERNMENT INVESTMENTS
TABLE 3 INVESTOR NETWORK FOR STEM CELL THERAPY MARKET: PRIVATE AND GOVERNMENT INVESTMENTS
TABLE 4 INVESTOR NETWORK FOR STEM CELL THERAPY MARKET: GOVERNMENT INVESTMENTS
TABLE 5 GLOBAL STEM CELL THERAPY MARKET, BY MODE OF THERAPY, 2013–2020 ($MILLION)
TABLE 6 GLOBAL STEM CELL THERAPY MARKET, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 7 GLOBAL ALLOGENEIC STEM CELL THERAPY MARKET, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 8 GLOBAL ALLOGENEIC STEM CELL THERAPY MARKET, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 9 ALLOGENEIC STEM CELL THERAPY MARKET FOR EYE DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 10 ALLOGENEIC STEM CELL THERAPY MARKET FOR GIT DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 11 ALLOGENEIC STEM CELL THERAPY MARKET FOR IMMUNE SYSTEM DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 12 ALLOGENEIC STEM CELL THERAPY MARKET FOR METABOLIC DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 13 ALLOGENEIC STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS , BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 14 ALLOGENEIC STEM CELL THERAPY MARKET FOR CNS DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 15 ALLOGENEIC STEM CELL THERAPY MARKET FOR CVS DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 16 ALLOGENEIC STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 17 ALLOGENEIC STEM CELL THERAPY MARKET FOR OTHER DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 18 GLOBAL AUTOLOGOUS STEM CELL THERAPY MARKET, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 19 GLOBAL AUTOLOGOUS STEM CELL THERAPY MARKET, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 20 AUTOLOGOUS STEM CELL THERAPY MARKET FOR GIT DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 21 AUTOLOGOUS STEM CELL THERAPY MARKET FOR CNS DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 22 AUTOLOGOUS STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS , BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 23 AUTOLOGOUS STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 24 AUTOLOGOUS STEM CELL THERAPY MARKET FOR CVS DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 25 AUTOLOGOUS STEM CELL THERAPY MARKET FOR OTHER DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 26 GLOBAL STEM CELL THERAPY MARKET, BY APPLICATION, 2013–2020 ($MILLION)
TABLE 27 STEM CELL THERAPY MARKET FOR EYE DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 28 STEM CELL THERAPY MARKET FOR GIT DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 29 STEM CELL THERAPY MARKET FOR IMMUNE SYSTEM DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 30 STEM CELL THERAPY MARKET FOR METABOLIC DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 31 STEM CELL THERAPY MARKET FOR MUSCULOSKELETAL DISORDERS, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 32 STEM CELL THERAPY MARKET FOR CNS DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 33 STEM CELL THERAPY MARKET FOR CVS DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 34 STEM CELL THERAPY MARKET FOR WOUNDS & INJURIES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 35 STEM CELL THERAPY MARKET FOR OTHER DISEASES, BY GEOGRAPHY, 2013–2020 ($MILLION)
TABLE 36 REGULATORY LANDSCAPE IN U.S. – FDA GUIDANCE DOCUMENTS
TABLE 37 NORTH AMERICA: STEM CELL THERAPY MARKET, BY MODE OF THERAPY, 2013–2020 ($MILLION)
TABLE 38 NORTH AMERICA: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 39 NORTH AMERICA: STEM CELL THERAPY MARKET, BY ALLOGENEIC THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 40 NORTH AMERICA: STEM CELL THERAPY MARKET, BY AUTOLOGOUS THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 41 EUROPE: STEM CELL THERAPY MARKET, BY MODE OF THERAPY, 2013–2020 ($MILLION)
TABLE 42 EUROPE: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 43 EUROPE: STEM CELL THERAPY MARKET, BY ALLOGENEIC THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 44 EUROPE: STEM CELL THERAPY MARKET, BY AUTOLOGOUS THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 45 ASIA-PACIFIC: STEM CELL THERAPY MARKET, BY MODE OF THERAPY, 2013–2020 ($MILLION)
TABLE 46 ASIA-PACIFIC: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 47 ASIA-PACIFIC: STEM CELL THERAPY MARKET, BY ALLOGENEIC THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 48 ASIA-PACIFIC: STEM CELL THERAPY MARKET, BY AUTOLOGOUS THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 49 RoW: STEM CELL THERAPY MARKET, BY MODE OF THERAPY, 2013–2020 ($MILLION)
TABLE 50 RoW: STEM CELL THERAPY MARKET, BY THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 51 RoW: STEM CELL THERAPY MARKET, BY ALLOGENEIC THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 52 RoW: STEM CELL THERAPY MARKET, BY AUTOLOGOUS THERAPEUTIC APPLICATION, 2013–2020 ($MILLION)
TABLE 53 PRODUCT APPROVALS
TABLE 54 PARTNERSHIPS, COLLABORATIONS, & AGREEMENTS
TABLE 55 ACQUISITIONS
TABLE 56 PATENTS
TABLE 57 OTHER DEVELOPMENTS

List of Figures (32)

Figure 1 Market Segmentation, By Application
Figure 2 Market Segmentation, By Mode of Therapy
Figure 3 Pipeline Analysis, Based on Regulatory Authority, 2011-2013
Figure 4 Pipeline Analysis, Based on Country, 2011-2013
Figure 5 Pipeline Analysis, Based on Phase Under Clinical Trial, 2011-2013
Figure 6 Pipeline Analysis, Based on No. of Patients Enrolled, 2011-2013
Figure 7 Pipeline Analysis, Overall Therapy Based on Source of Cell Extraction, 2011-2013
Figure 8 Pipeline Analysis, Allogeinic Therapy Based on Clinical Trial Phases, 2011-2013
Figure 9 Pipeline Analysis, Autologous Therapy Based on Clinical Trial Phases, 2011-2013
Figure 10 Pipeline Analysis, By Application, 2011-2013
Figure 11 Pipeline Analysis, Allogeinic Therapy Based on Therapeutic Areas, 2011-2013
Figure 12 Pipeline Analysis, Autologous Therapy Based on Therapeutic Areas, 2011-2013
Figure 13 Overall Market: Based on Cell Lines Used, 2011-2013
Figure 14 Allogeneic Stem Cell Therapy Market: Based on Cell Lines Used, 2011-2013
Figure 15 Autologous Stem Cell Therapy Market: Based on Cell Lines Used, 2011-2013
Figure 16 Pipeline Analysis of Stem Cell Therapy Market: Based on Major Companies, 2011-2013
Figure 17 Investor Network for Stem Cell Therapy Market: Nih (U.S.) Funding
Figure 18 Market Segmentation, By Mode of Therapy
Figure 19 Comparison Between Allogeneic & Autologous Stem Cell Therapy Market
Figure 20 Estimated Cost Involved in The Manufacturing of Stem Cell Therapy Product
Figure 21 Allogeneic Stem Cell Therapy Market Segmentation, By Mode of Therapy
Figure 22 Autologous Stem Cell Therapy Market Segmentation, By Mode of Therapy
Figure 23 Market Segmentation, By Mode of Therapy
Figure 24 Stem Cell Therapy Process
Figure 25 Stem Cell Research Policies and Legislations
Figure 26 Geographic Distribution of CTG-Registered Stem Cell Therapy-Based Clinical Trials, 2000-2012
Figure 27 Evolution of Stem Cell Research, North America
Figure 28 Evolution of Stem Cell Research, Europe
Figure 29 Evolution of Stem Cell Research, Asia-Pacific
Figure 30 Key Growth Strategies, 2010-2014
Figure 31 Share of Key Companies in Patents Category, 2010-2014
Figure 32 Share of Key Companies in Product Approvals Category, 2010-2014

To order this report: Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020
http://www.reportlinker.com/p02182905/Stem-Cell-Therapy-Market-by-Treatment-Mode-Autologous--Allogeneic-Therapeutic-Applications-CNS-CVS-GIT-Wound-Healing-Musculoskeletal-Eye--Immune-System---Regulatory-Landscape-Pipeline-Analysis--Global-Forecasts-to-2020.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.